In summary, the rapid development of EGFR-TKIs has revolutionized the treatment patterns of EGFR-mutated NSCLC, which improved the survival and quality of life of this population. Nevertheless, similar to early-generation EGFR-TKIs, intractable matters of acquired resistance to osimertinib also inevitab...
6]. For individuals with advanced EGFR-mutated NSCLC, targeted therapy utilizing EGFR tyrosine kinase inhibitors (TKIs) serves as a cornerstone of first-line treatment. These therapies have demonstrated
Dr. Shannon Westin and her guest, Dr. Helena Yu discuss the paper "HERTHENA-Lung01, a Phase 2 Trial of Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Fo
Advanced non鈥搒mall-cell lung cancer (NSCLC) harboring activating mutations of epidermal growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs), namely erlotinib and gefitinib. The purpose of this meta-analysis was to evaluate the benefit of EGFR TKIs in EGFR...
Background Osimertinib is a key-drug to treat NSCLC harboring EGFR sensitizing mutation at 1st line setting as well as T790M resistant mutation at late line. Interstitial lung disease/pneumonitis (ILD) is a fatal adverse event induced by tyrosine kinase inhibitors including osimertinib especially in ...
[2]P. Janne, D. Planchard, Y. Cheng, et al. FLAURA2: safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC. 2023 ESMO. Abstract LBA68. 内容制作 封面图片:摄图网
[2]P. Janne, D. Planchard, Y. Cheng, et al. FLAURA2: safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC. 2023 ESMO. Abstract LBA68. 内容制作 封面图片:摄图网 责任编辑:
Therefore, adopting a clinical point of view, this paper aims to provide a comprehensive review on the previous, the current and the possible future role of liquid biopsy in the framework of the diagnostic鈥搕herapeutic algorithm of EGFR+ advanced NSCLC....
In 34 % of advanced NSCLC patients, we detected mutations in cfDNA not previously detected in tumor samples and double mutations in 17 %. Patients with baseline total EGFR copy levels above the median presented decreased overall survival (OS) (341 vs. 870 days, p < 0.05) and progression-...
The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution mutations...